Given the known sequence and functional similarities between the N-acetylneuraminic acid binding domain on the spike protein of SARS-CoV-2 and human galectin-336, it is possible that by targeting galectin-3, we might also interfere with viral-host interactions, thus potentially decreasing viral load and the resulting inflammatory responses associated with the infection. The gene discussed is LGALS3; the disease is infection.